White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...
In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst ...
Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...
An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery. In today's Pharmaceutical ...
Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...
Pharmaceutical Executive: What elements is the conversation about bringing pharma manufacturing home missing? Charlie Lyon: ...
In March of this year, the API Innovation Center released its whitepaper titled, “From Fragility to Resilience: Aligning ...
Natalie de Graaf is VP and GM of Data, AI and ML; Solutions for Health and National Security at the API Innovation Center. Natalie de Graaf, from the API Innovation Center, discusses a recent ...
ASPENOVA randomizes Cyclin E1-positive PROC to azenosertib versus paclitaxel, PLD, gemcitabine, or topotecan, reflecting current NCCN sequential single-agent practice. PFS is the primary endpoint, ...
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...
There are two main changes required to break the operational cost barrier. The first is technology-enabled automation. By ...
Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the conversation, he explained the issues the payers face with cell & gene therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results